AbbVie Boosts Biologics with $223M Investment in Singapore

• AbbVie, a global biopharmaceutical contract manufacturer, is investing $223 million in a new biologics manufacturing facility in Singapore.
• The expansion will add over 100 jobs and new biologics manufacturing capacity to AbbVie’s global network.
• The construction will commence immediately with facilities becoming operational in 2026.

AbbVie has announced a significant investment of $223 million in a new biologics manufacturing facility in Singapore. The expansion will add more than 100 jobs and new biologics manufacturing capacity to AbbVie’s global network. The construction will commence immediately with facilities becoming operational in 2026.

The new investment will add 24,000 litres of biologics drug-substance capacity to AbbVie’s global manufacturing network and support current products as well as emerging immunology and oncology compounds within AbbVie’s pipeline. This expansion is a part of AbbVie’s continued commitment to drug development and the global supply and management of life-changing therapies.

Located in Singapore’s Tuas Biomedical Park, AbbVie’s Singapore plant is a state-of-the-art small-molecule and biologics manufacturing facility serving markets worldwide. Once completed, the expanded Singapore manufacturing facility will employ more than 500 people in manufacturing, quality assurance, supply chain, engineering, and administration roles.

Azita Saleki-Gerhardt, Ph.D., AbbVie Executive Vice President, Chief Operations Officer, said, “The expansion of our Singapore site will strengthen our global manufacturing capabilities, support our growing biologics pipeline and help AbbVie continue delivering on our patient commitments now and in the future”.

With this announcement, AbbVie has invested more than $740 million in acquiring, modernizing, and expanding its Singapore facility over the past 10 years. This expansion represents one of AbbVie’s many investments in its Singapore-based operations and the proud continuation of their decade-long partnership with the Government of Singapore.